Celexa

(citalopram)

ApprovedSmall molecule

Citalopram is used to treat depression and anxiety disorders by helping to balance chemicals in the brain that affect mood and emotions.[2] Celexa is currently approved and in use across 40 indications[4].[1]

Celexa is one of 842 small molecule programs targeting Frontotemporal Dementia. It is currently in Approved.

Indications

127

Total Trials

Active Trials

841

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Frontotemporal DementiaActive, not recruiting

Depressive DisorderActive, not recruiting

Mood DisorderActive, not recruiting

SuicideActive, not recruiting

StrokeApproved

Acute Coronary SyndromeActive, not recruiting

Chest PainActive, not recruiting

Parkinson DiseaseActive, not recruiting

Brain InjuryActive, not recruiting

Borderline Personality DisorderActive, not recruiting

Frontotemporal DementiaApproved

Active, not recruiting

Depressive DisorderPhase 1

Active, not recruiting

Mood DisorderPhase 2

Active, not recruiting

SuicidePhase 2/Phase 3

Active, not recruiting

StrokeApproved

Approved

Acute Coronary SyndromePhase 1

Active, not recruiting

Chest PainApproved

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Brain InjuryApproved

Active, not recruiting

Borderline Personality DisorderApproved

Active, not recruiting

Showing 10 of 39 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Celexa

AbbVie

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Study completion

NCT06412315

Q3 2027

Recruiting

Infants

NCT03511118

Clinical

Trials by Indication[1]

Depression11 trials

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Terminated·MMassachusetts General Hospital·Phase 4·NCT00955474·32 enrolled

N-methylglycine (Sarcosine) Treatment for Depression

Completed·—·Phase 2·NCT00977353·40 enrolled

DRACULA1 Partum Depression: an Integrated Molecular-pharmaco-imaging Study")

Not yet recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico··NCT06131255·15 enrolled

Show 8 more trials

Microbiome of Depression & Treatment Response to Citalopram

Completed·MMayo Clinic··NCT02330068·34 enrolled

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03854578·73 enrolled

Trial of Citalopram for the Prevention of Depression

Completed·MMarina Klein·Phase 3·NCT00317746·76 enrolled

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00021528·4,000 enrolled

Magnetic Stimulation Therapy for Treating Vascular Depression

Completed·UUniversity of Iowa·Phase 3·NCT00044798·132 enrolled

DECIFER: Depression and Citalopram In First Episode Recovery

Completed·NNYU Langone Health·Phase 4·NCT01041274·95 enrolled

Functional MRI Before and After Treatment for Depression

Terminated·SStanford University·N/A·NCT00896441·31 enrolled

Citalopram vs Clomipramine vs Placebo in Recurrent Depression

Completed·UUniversity of Aarhus·N/A·NCT01575158·59 enrolled

Major Depressive Disorder9 trials

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Completed·UUniversity of Chicago·Phase 2·NCT01742832·79 enrolled

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01764867·1,080 enrolled

Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder

Unknown status·FFidia Farmaceutici s.p.a.·Phase 4·NCT04975724·150 enrolled

Show 6 more trials

A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)

Completed·CCentre for Addiction and Mental Health·Phase 1·NCT02269540·10 enrolled

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Completed· Biogen logo

Biogen·Phase 3·NCT04476030·440 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00351910·494 enrolled

Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

Completed·PPharmaNeuroBoost N.V.·Phase 2·NCT00672659·165 enrolled

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Completed·PPharmaNeuroBoost N.V.·Phase 3·NCT01312922·555 enrolled

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Completed·FForest Laboratories·Phase 4·NCT01473381·1,162 enrolled

Antidepressants5 trials

Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression

Terminated·—·Phase 4·NCT01099592·7 enrolled

Antidepressants and Bone Mineral Density

Completed·GGuiyang Medical University·Phase 3·NCT02179268·203 enrolled

Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD

Completed·SSykehuset Innlandet HF·Phase 4·NCT00433121·24 enrolled

Show 2 more trials

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01725048·21 enrolled

Antidepressants, Emotions and Personality

Completed·UUniversity of Oxford·N/A·NCT01946607·42 enrolled

Schizophrenia4 trials

Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia

Completed·IImperial College London·Phase 4·NCT01032083·62 enrolled

Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia

Completed·NNational Institute of Mental Health and Neuro Sciences, India·Phase 4·NCT00893256·48 enrolled

Antidepressant Treatment in Older Adults With Schizophrenia

Completed·VVeterans Medical Research Foundation·N/A·NCT00047450·212 enrolled

Show 1 more trial

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Unknown status·FFundació Sant Joan de Déu·Phase 4·NCT01300364·249 enrolled

Stroke4 trials

Post-stroke Depression Treatment Effect on Stroke Recurrence

Completed·—·N/A·NCT04776226·1,230 enrolled

SSRIs and TDCS Enhance Post-stroke Motor Recovery

Unknown status·CChih-Wei Tang·Phase 3·NCT05041582·80 enrolled

The Efficacy of Citalopram Treatment in Acute Stroke

Completed·UUniversity of Aarhus·Phase 2·NCT01937182·642 enrolled

Show 1 more trial

The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression

Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00254020·138 enrolled

68 more indications

ESS4 trials

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02028026

REward Processing And Citalopram Study

Unknown status·UUniversity of Oxford·Phase 1/2·NCT06017037·40 enrolled

Combined Antidepressant and Behavioural Intervention

Completed·UUniversity of Oxford·N/A·NCT05627154·134 enrolled

Show 1 more trial

Ethnic Variations in Antidepressant Response

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00047671·400 enrolled

Major Depression3 trials

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

Completed·ZZentrum für Integrative Psychiatrie·N/A·NCT00993876·45 enrolled

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

Completed·MMclean Hospital·Phase 4·NCT01557946·32 enrolled

PUFA Augmentation in Treatment of Major Depression

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 3·NCT00067301·60 enrolled

Medication3 trials

Brain Response to Serotonergic Medications in ASD

Unknown status·KKing's College London·N/A·NCT04145076·100 enrolled

A Study of Medication With or Without Psychotherapy for Complicated Grief

Completed·NNew York State Psychiatric Institute·Phase 2·NCT01179568·395 enrolled

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

Unknown status·HHolsboerMaschmeyer NeuroChemie GmbH·Phase 4·NCT02237937·80 enrolled

Emotional Processing3 trials

Citalopram and Self Emotional Processing

Unknown status·UUniversity of Oxford·N/A·NCT04169230·44 enrolled

PF-04995274 and Emotional Processing in Un-medicated Depression

Completed·UUniversity of Oxford·Phase 1·NCT03516604·90 enrolled

Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic

Completed· GSK logo

GSK·Phase 1·NCT01424384·54 enrolled

Cocaine Dependence3 trials

Brain Function and Structure in Cocaine Dependence

Completed·VVirginia Commonwealth University·Phase 2·NCT02080832·54 enrolled

Serotonin, Impulsivity, and Cocaine Dependence Treatment

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00297505·120 enrolled

Citalopram for Cocaine Dependence

Completed·JJoy Schmitz·Phase 2·NCT01535573·108 enrolled

AIN2 trials

Brain Effects of Escitalopram and Citalopram Using fMRI

Completed·—·Phase 4·NCT00825825·27 enrolled

Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00218036·54 enrolled

Dementia2 trials

Treating Behavioral Disturbances in Individuals With Dementia

Completed·UUniversity of Pittsburgh·Phase 2·NCT00073658·137 enrolled

Dementia Antipsychotics And Antidepressants Discontinuation Study

Completed·SSykehuset Innlandet HF·Phase 4·NCT00594269·149 enrolled

Adolescent2 trials

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

Completed·UUniversity of Pittsburgh·Phase 2/3·NCT00018902·334 enrolled

Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents

Withdrawn·SSunnybrook Health Sciences Centre·Phase 3·NCT00249886·60 enrolled

Drug Interactions2 trials

A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT03907215·24 enrolled

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

Completed·FFood and Drug Administration (FDA)·Phase 1·NCT06192589·241 enrolled

Cognition2 trials

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00602290·181 enrolled

Citalopram to Enhance Cognition in HD

Completed·UUniversity of Iowa·Phase 2·NCT00271596·33 enrolled

Agitation2 trials

Citalopram for Agitation in Alzheimer's Disease

Completed·JJHSPH Center for Clinical Trials·Phase 3·NCT00898807·186 enrolled

Serotonergic Pharmacotherapy for Agitation of Dementia

Completed·BBruce Pollock·Phase 3·NCT00009204

Bipolar Disorder2 trials

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated·UUniversity of New Mexico··NCT02893371·1,037,352 enrolled

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

Completed·NNew York State Psychiatric Institute·Phase 4·NCT02473250·40 enrolled

Age2 trials

PPI's and SSRI's Therapy for the Management of NCCP

Terminated·EEvangelismos Hospital·Phase 4·NCT02825342·60 enrolled

Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers

Completed·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT04355455·14 enrolled

Brain Injury2 trials

Depression and Traumatic Brain Injury

Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00254007·200 enrolled

Antidepressant Maintenance in Traumatic Brain Injury

Unknown status·OOntario Neurotrauma Foundation·Phase 4·NCT00162916·21 enrolled

Rheumatoid Arthritis1 trial

Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes

Unknown status·VVrije Universiteit Brussel·N/A·NCT01154647·70 enrolled

Breast Cancer1 trial

Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression

Terminated·HHospital Universitari de Bellvitge·Phase 2·NCT05063604·40 enrolled

Elective1 trial

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 4·NCT03779789·362 enrolled

Prevention1 trial

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

Completed·SShanghai Mental Health Center·Phase 4·NCT02022709·78 enrolled

Placebo Effect1 trial

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01919216·65 enrolled

Short Bowel Syndrome1 trial

Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome

Withdrawn·UUniversity of Nebraska·N/A·NCT00876226

Menstrual Cycle1 trial

Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response

Completed·UUniversity Health Network, Toronto·N/A·NCT00188396·44 enrolled

Chronic1 trial

Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders

Completed·VVrije Universiteit Brussel··NCT01601912·59 enrolled

Suicide1 trial

Treatment of Adolescent Suicide Attempters (TASA)

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00080158·120 enrolled

Tics1 trial

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01951053·18 enrolled

Treatment1 trial

Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)

Unknown status·MMedical University of Vienna·Phase 4·NCT02711215·80 enrolled

Ischemic stroke1 trial

Effect of Serotonin and Levodopa in Ischemic Stroke

Completed·HHospital de Granollers·Phase 4·NCT02386475·39 enrolled

Borderline personality disorder1 trial

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00834834·84 enrolled

Drug Therapy1 trial

Drug Therapy to Treat Minor Depression

Completed·MMassachusetts General Hospital·N/A·NCT00048815·73 enrolled

Asthma1 trial

Study of Treatment of Depression in Refractory Asthma

Unknown status·LLiam Heaney·N/A·NCT01153165·40 enrolled

Infants1 trial

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting·—··NCT03511118·1,600 enrolled

Alcohol1 trial

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

Completed·VVA Office of Research and Development·Phase 1·NCT01657760·31 enrolled

Frontotemporal Dementia1 trial

Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia

Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00376051·22 enrolled

Acupuncture1 trial

Auricular Concha Electro-acupuncture for the Treatment of Depression

Unknown status·CChina Academy of Chinese Medical Sciences·Phase 1·NCT03607331·106 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Terminated· Novartis logo

Novartis·Phase 4·NCT01436643·54 enrolled

Pain1 trial

Myofascial Pain Patients' Response to the Administration of Low Doses of Amitriptyline and Citalopram Compared With the Use of Bite Splint

Unknown status·UUniversity of Coimbra·Phase 2/3·NCT04777838·80 enrolled

Parkinson disease1 trial

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Completed·UUniversity of Michigan·Phase 2·NCT04497168·58 enrolled

Burning Mouth Syndrome1 trial

Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome

Unknown status·FFederico II University·Phase 3·NCT06025474·203 enrolled

Hypersensitivity1 trial

Citalopram for Reflux Hypersensitivity and Functional Heartburn

Unknown status·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT03499171·100 enrolled

Randomized1 trial

Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT02113943·24 enrolled

Chest pain1 trial

Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

Terminated·—·Phase 4·NCT05735756·1 enrolled

Intravenous1 trial

Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults

Terminated·RRotman Research Institute at Baycrest·N/A·NCT01216449·29 enrolled

Single Dose1 trial

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Completed·UUniversity Hospital Bispebjerg and Frederiksberg·Phase 1·NCT04097288·24 enrolled

Prurigo Nodularis1 trial

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Unknown status·HHadassah Medical Organization·N/A·NCT00532519

MPA1 trial

Comparison of Fluoxetine Versus Citalopram Therapy to Control Postmenopausal Vasomotor Syndrome

Completed·HHospital Regional 1o de Octubre·N/A·NCT05346445·91 enrolled

Anxiety1 trial

Serotonin, Anxiety and Visceral Sensation

Completed·—·N/A·NCT06212284·31 enrolled

Adverse Events1 trial

Citalopram and the Risk of Serious Adverse Events

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's··NCT07399795·7,110 enrolled

Function1 trial

Alcohol and Gender Effects on Stress Circuit Function

Completed·UUniversity of Cincinnati·N/A·NCT00226694·96 enrolled

Severe Depression1 trial

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00666757·750 enrolled

Treatment Outcome1 trial

Neuroimaging Predictors of Antidepressant Treatment Outcome

Withdrawn·UUniversity of Michigan·Phase 2·NCT02000726

Anxiety Disorder1 trial

Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury

Unknown status·WWalter Reed Army Medical Center·N/A·NCT00208572·104 enrolled

Parkinson's Disease1 trial

Improving Quality of Life in Early Parkinson's Disease

Unknown status·WWestern University, Canada·N/A·NCT04590612·30 enrolled

Acute Coronary Syndrome1 trial

Citalopram for Sx/Util in Acute Coronary Syndrome Patients

Withdrawn·HHenry Ford Health System·Phase 1/2·NCT01667744

Alcohol Abuse1 trial

STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse

Completed·NNew York State Psychiatric Institute··NCT00369746·674 enrolled

Completed·CColumbia Northwest Pharmaceuticals·Phase 2·NCT01189812·80 enrolled

Morbidity1 trial

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Completed·UUniversity of Washington·N/A·NCT02655354·635 enrolled

Autism Spectrum Disorder1 trial

Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00609531·12 enrolled

Irritable Bowel Syndrome1 trial

Citalopram in Irritable Bowel Syndrome

Completed·SStanford University·Phase 2·NCT00477165·54 enrolled

Memory Impairment1 trial

Combination Treatment Study for Memory Impairment and Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01658228·86 enrolled

Hot flashes1 trial

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Active, not recruiting· Astellas logo

Astellas··NCT06049797·999 enrolled

Abdominal pain1 trial

Anxiety and Recurrent Abdominal Pain in Children

Completed·—·Phase 2/3·NCT00962039·81 enrolled

Alzheimer's Disease1 trial

CATIE-Alzheimer's Disease Trial

Completed·NNational Institute of Mental Health (NIMH)·N/A·NCT00015548·450 enrolled

Depressive Disorder1 trial

Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain

Unknown status·CChina Academy of Chinese Medical Sciences·Phase 1·NCT03282110·60 enrolled

Treatment Resistant Depression1 trial

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown status·HHospital de Clinicas de Porto Alegre·N/A·NCT01896349·74 enrolled

Stress1 trial

Citalopram and Stress Reactivity

Unknown status·UUniversity of Oxford·N/A·NCT04161209·40 enrolled

Interaction1 trial

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Completed·RRadboud University Medical Center·Phase 1·NCT01978782·24 enrolled

Unspecified7 trials

7T Amygdala and Citalopram Study

Recruiting·UUniversity of Oxford·N/A·NCT06412315·50 enrolled

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Specific Effects of Escitalopram on Neuroendocrine Response

Completed·QQueen's University··NCT00150527·8 enrolled

Show 4 more trials

Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00538889·40 enrolled

A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01367756·32 enrolled

Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin

Completed·—·Phase 1·NCT02092974·40 enrolled

Effects of Citalopram on Hostility and CHD Risk

Completed·UUniversity of Pittsburgh·N/A·NCT00217828

Regulatory

FDA Approval Timeline[5]

Dec 22, 1999

CELEXA

NDA NDA021046

Apr 27, 2000

CELEXA

NDA NDA020822

Dec 20, 2005

CITALOPRAM HYDROBROMIDE

NDA NDA021763

Jan 31, 2022

CITALOPRAM HYDROBROMIDE

NDA NDA215428

Sources

References

[1]
ClinicalTrials.gov — 127 trial records for citalopram. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Celexa drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — citalopram compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for citalopram. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA215428). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin Transporter Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Celexa

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Depression11 trials

Major Depressive Disorder9 trials

Antidepressants5 trials

Schizophrenia4 trials

Stroke4 trials

ESS4 trials

Major Depression3 trials

Medication3 trials

Emotional Processing3 trials

Cocaine Dependence3 trials

AIN2 trials

Dementia2 trials

Adolescent2 trials

Drug Interactions2 trials

Cognition2 trials

Agitation2 trials

Bipolar Disorder2 trials

Age2 trials

Brain Injury2 trials

Rheumatoid Arthritis1 trial

Breast Cancer1 trial

Elective1 trial

Prevention1 trial

Placebo Effect1 trial

Short Bowel Syndrome1 trial

Menstrual Cycle1 trial

Chronic1 trial

Suicide1 trial

Tics1 trial

Treatment1 trial

Ischemic stroke1 trial

Borderline personality disorder1 trial

Drug Therapy1 trial

Asthma1 trial

Infants1 trial

Alcohol1 trial

Frontotemporal Dementia1 trial

Acupuncture1 trial

Relapsing-Remitting Multiple Sclerosis1 trial

Pain1 trial

Parkinson disease1 trial

Burning Mouth Syndrome1 trial

Hypersensitivity1 trial

Randomized1 trial

Chest pain1 trial

Intravenous1 trial

Single Dose1 trial

Prurigo Nodularis1 trial

MPA1 trial

Anxiety1 trial

Adverse Events1 trial

Function1 trial

Severe Depression1 trial

Treatment Outcome1 trial

Anxiety Disorder1 trial

Parkinson's Disease1 trial

Acute Coronary Syndrome1 trial

Alcohol Abuse1 trial

ALS1 trial

Acute Kidney Injury1 trial

Mood Disorder1 trial

Morbidity1 trial

Autism Spectrum Disorder1 trial

Irritable Bowel Syndrome1 trial

Memory Impairment1 trial

Hot flashes1 trial

Abdominal pain1 trial

Alzheimer's Disease1 trial

Depressive Disorder1 trial

Treatment Resistant Depression1 trial

Stress1 trial

Interaction1 trial

Unspecified7 trials